SPRC — SciSparc Ltd.

Nasdaq · Health Care · Pharmaceuticals · CIK 1611746 ·
Last close
$7.12
Market Cap
$4.08M
52W High
$15.79
52W Low
$4.00
ADV30
330,092
Next earnings
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 7,622,000 4,591,000 2,475,000
Jun 2025 5,139,000 1,545,000 5,220,000
Dec 2024 10,347,000 1,540,000 1,408,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-87,154,000
Inventory
$75,000
Receivables
$662,000
ST Investments
$0
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$856,000
EBITDA
$-8,528,000
Free Cash Flow
$833,000
Enterprise Value
$1,670,214
Total Cash
$4,591,000
Total Debt
$366,000
Shares Out
573,243
Trailing EPS
$98.07
Book Value
$11.60
ROE
-178.4%
ROA
-60.7%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 856,000 -8,749,000 -12,179,000 7,622,000 2,475,000 -4,137,000
Dec 2024 1,306,000 -7,242,000 -6,284,000 10,347,000 1,408,000 -5,104,000
Dec 2023 2,879,000 -5,773,000 -5,122,000 11,182,000 1,595,000 -5,887,000
Dec 2022 1,347,000 -8,287,000 -2,592,000 10,605,000 4,156,000 -7,917,000
Dec 2021

Peers — same industry

TickerNameMarket CapLastDaily %
CVSI CV Sciences, Inc. $4.08M $0.02
ELAB PMGC Holdings Inc. $4.19M $0.92
RDHL RedHill Biopharma Ltd. $3.95M $0.65
ENSC Ensysce Biosciences, Inc. $3.89M $0.25
CTTH CTT PHARMACEUTICAL HOLDINGS, INC. $3.87M $0.07

News headlines (Yahoo Finance, 1h cache)

SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
2026-07-31 12:20 · Yahoo
SciSparc Advances Quantum Clinical Data Analytics as NeuroThera Validates Proprietary Computing Platform
2026-07-29 14:30 · Yahoo
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
2026-07-29 12:32 · Yahoo
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
2026-07-27 12:25 · Yahoo
NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
2026-07-15 13:27 · Yahoo
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
2026-07-15 12:41 · Yahoo
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
2026-06-04 11:32 · Yahoo
NeuroThera Labs Inc. Announces Closing of Acquisition of Majority Stake in CliniQuantum Ltd.
2026-06-03 22:04 · Yahoo
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
2026-05-28 12:40 · Yahoo
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
2026-03-16 12:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.